BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. More Details
Slightly overvalued with limited growth.
Share Price & News
How has BioCryst Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BCRX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: BCRX's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
7 Day Return
1 Year Return
Return vs Industry: BCRX exceeded the US Biotechs industry which returned 24.2% over the past year.
Return vs Market: BCRX exceeded the US Market which returned 36.2% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is BioCryst Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 days ago | Simply Wall StRead This Before Selling BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares
1 month ago | Simply Wall StCan You Imagine How Jubilant BioCryst Pharmaceuticals' (NASDAQ:BCRX) Shareholders Feel About Its 199% Share Price Gain?
2 months ago | Simply Wall StHere's What BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Shareholder Ownership Structure Looks Like
Is BioCryst Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BCRX ($11.15) is trading below our estimate of fair value ($79.72)
Significantly Below Fair Value: BCRX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BCRX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: BCRX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BCRX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BCRX has negative assets, so we can't compare its PB Ratio to the US Biotechs industry average.
How is BioCryst Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BCRX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BCRX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BCRX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BCRX's revenue (42.4% per year) is forecast to grow faster than the US market (10% per year).
High Growth Revenue: BCRX's revenue (42.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BCRX's Return on Equity is forecast to be high in 3 years time
How has BioCryst Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BCRX is currently unprofitable.
Growing Profit Margin: BCRX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BCRX is unprofitable, and losses have increased over the past 5 years at a rate of 23.8% per year.
Accelerating Growth: Unable to compare BCRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BCRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-13.6%).
Return on Equity
High ROE: BCRX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is BioCryst Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: BCRX has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: BCRX has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: BCRX has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: BCRX's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BCRX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: BCRX has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 24.6% each year.
What is BioCryst Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BCRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BCRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BCRX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BCRX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BCRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jon Stonehouse (59 yo)
Mr. Jon P. Stonehouse has been the Chief Executive Officer and Executive Director of BioCryst Pharmaceuticals, Inc. at Shionogi & Co., Ltd. since joining in January 8, 2007 and also has been its President ...
CEO Compensation Analysis
Compensation vs Market: Jon's total compensation ($USD2.28M) is below average for companies of similar size in the US market ($USD3.62M).
Compensation vs Earnings: Jon's compensation has been consistent with company performance over the past year.
|CEO, President & Director||14.17yrs||US$2.28m||0.44% |
|Chief Medical Officer & Senior VP||12.67yrs||US$1.07m||0.0065% |
|Senior Vice President of Drug Discovery||7.42yrs||US$1.08m||0.10% |
|Senior VP & Chief Business Officer||1.67yrs||US$2.18m||0.025% |
|Senior VP & CFO||0.92yr||no data||0.030% |
|Executive Director of Finance & Principal Accounting Officer||1.17yrs||no data||0.00048% |
|Senior Vice President of Investor Relations & Corporate Communications||no data||no data||no data|
|Senior VP||14.5yrs||US$1.33m||0.061% |
|Vice President of Human Resources||no data||no data||no data|
|Senior Vice President of Regulatory Affairs||no data||no data||no data|
|Senior VP & Chief Commercial Officer||1.17yrs||no data||0.072% |
Experienced Management: BCRX's management team is considered experienced (4.5 years average tenure).
|CEO, President & Director||14.17yrs||US$2.28m||0.44% |
|Independent Director||2.17yrs||US$280.19k||0.018% |
|Independent Chairman||3.83yrs||US$154.09k||0.042% |
|Independent Director||1.08yrs||no data||no data|
|Independent Director||9.75yrs||US$134.09k||0.0086% |
|Independent Director||9.42yrs||US$129.71k||0.0056% |
|Independent Director||1.5yrs||US$95.30k||no data|
|Independent Director||2.25yrs||US$119.71k||0.0078% |
|Independent Director||9.17yrs||US$134.09k||0.036% |
Experienced Board: BCRX's board of directors are considered experienced (3.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.2%.
BioCryst Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: BioCryst Pharmaceuticals, Inc.
- Ticker: BCRX
- Exchange: NasdaqGS
- Founded: 1986
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.979b
- Shares outstanding: 177.52m
- Website: https://www.biocryst.com
Number of Employees
- BioCryst Pharmaceuticals, Inc.
- 4505 Emperor Boulevard
- Suite 200
- North Carolina
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BCRX||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Mar 1994|
|BO1||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Mar 1994|
|BCRX *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Mar 1994|
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of a...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/03/09 00:01|
|End of Day Share Price||2021/03/08 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.